 
Marksans Pharma Ltd. 
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, 
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000  
E-mail: companysecretary@marksanspharma.com 
www.marksanspharma.com 
 
November 19, 2025 
 
BSE Limited National Stock Exchange of India Limited 
Corporate Relation Department Listing Department  
Phiroze Jeejeebhoi Towers, Exchange Plaza, C-1, Block-G, 
Dalal Street, Bandra-Kurla Complex,  
Mumbai - 400001. Bandra (East), Mumbai - 400051. 
Scrip Code: 524404 Symbol: MARKSANS  
 
Sub: Press Release 
 
Marksans Pharma Limited ’s wholly owned subsidiary Marksans Pharma Inc. receives 
USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC). 
 
Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: 
MARKSANS; BSE: 524404) hereby announces the final approval of the Company’s  wholly 
owned subsidiary Marksans Pharma Inc.’s Abbreviated New Drug  Application (ANDA) for 
Loperamide Hydrochloride Tablets USP, 2 mg (OTC). 
 
This product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2mg, 
of Kenvue Brands LLC (Kenvue) NDA - 019860. 
 
Loperamide Hydrochloride is an anti-diarrheal medication used to control symptoms of acute 
and chronic diarrhea. 
 
Thanking you, 
Yours faithfully 
For Marksans Pharma Limited 
 
 
 
Harshavardhan Panigrahi 
Company Secretary 
 
About Marksans Pharma Ltd 
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is 
engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in 
the global markets. The company's manufacturing facilities located in India, USA and UK are 
approved by several leading regulatory agencies including USFDA, UKMHRA and 
Australian TGA. The C ompany's robust product portfolio spreads over major therapeutic 
segments of CVS, CNS, Anti -diabetic, Pain Management, Upper respiratory , 
Gastroenterological, Oncology, Anti -biotic, etc . The C ompany is marketing these products 
globally. 
